← Back to Search

Behavioral Intervention

Message encouraging vaccination in preparation for the holidays for COVID-19

N/A

Waitlist Available

Research Sponsored by University of Pennsylvania

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

• Patient of a large retail pharmacy that has opted into receving SMS messages from the pharmacy and has received their primary COVID vaccination series.

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 90 days after receiving the sms/mms intervention

Awards & highlights

Study Summary

This megastudy is a massive randomized controlled trial. By randomizing participants to 10 different intervention conditions simultaneously, the investigators will be able to compare the effectiveness of different interventions to one another and to a control group (in which individuals will only receive the usual communications from their partner organization) to identify which interventions significantly increase vaccination rates. Pharmacy customers will be randomly assigned to receive one of the interventions designed by team scientists to encourage vaccination or to a control group. The baseline intervention will be based on the top-performing SMS intervention identified in the investigators previous megastudies on encouraging vaccination (Milkman et al., 2021b, 2022). Pharmacy customers will receive SMS messages conveying that a COVID booster vaccine is reserved or waiting for them at the pharmacy. Additional behavioral science messaging strategies will be tested by building off of this baseline intervention.

Eligible Conditions

COVID-19
Coronavirus

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 90 days after receiving the sms/mms intervention

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~90 days after receiving the sms/mms intervention

This trial's timeline: 3 weeks for screening, Varies for treatment, and 90 days after receiving the sms/mms intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Secondary outcome measures

Patient uptake of the COVID bivalent booster

Trial Design

11Treatment groups

Experimental Treatment

Active Control

Group I: Planning message recommending same time/location as last vaccinationExperimental Treatment1 Intervention

This condition will use a text message recommending the same time and location as the participant's last vaccination to get a COVID vaccination.

Group II: Message offering free round trip ride to the pharmacyExperimental Treatment1 Intervention

This condition will use a text message offering a free round trip ride to the pharmacy to get a COVID vaccination.

Group III: Message including link to resources combating misinformation with a GIFExperimental Treatment1 Intervention

This condition will use a text message including a link to to resources combating misinformation and then recommend a COVID vaccination and will include a GIF.

Group IV: Message including link to resources combating misinformationExperimental Treatment1 Intervention

This condition will use a text message including a link to to resources combating misinformation and then recommend a COVID vaccination.

Group V: Message from local pharmacy teamExperimental Treatment1 Intervention

This condition will use a text message from the participant's local pharmacist recommending a COVID vaccination.

Group VI: Message encouraging vaccination in preparation for the holidaysExperimental Treatment1 Intervention

This condition will use a text message to encourage a COVID vaccination in preparation for the holidays.

Group VII: Message conveying the CDC recommends vaccinationExperimental Treatment1 Intervention

This condition will use a text message to encourage a COVID vaccination by conveying the CDC recommends vaccination.

Group VIII: Message communicating latest data on COVID transmission in patient's areaExperimental Treatment1 Intervention

This condition will use a text message informing the participant of the latest data on COVID transmission in participant's area and recommend a COVID vaccination.

Group IX: Control condition with "waiting for you" message with a GIFExperimental Treatment1 Intervention

This control condition will use the text message that we've found to be the best performing in our last mega-study of vaccine text messages and includes a GIF to recommend a COVID vaccination.

Group X: Control condition with "waiting for you" messageExperimental Treatment1 Intervention

This control condition will use the text message that we've found to be the best performing in our last mega-study of vaccine text messages to recommend a COVID vaccination.

Group XI: Holdout control condition with no messageActive Control1 Intervention

Participants will only receive the standard pharmacy messaging.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

COVID Booster text messages

2022

N/A

~4980000

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor

2,000 Previous Clinical Trials

40,280,088 Total Patients Enrolled

32 Trials studying COVID-19

3,674,017 Patients Enrolled for COVID-19

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there currently any openings within this research study?

"Clinicaltrials.gov states that this particular trial, which was first posted on November 3rd 2022 and most recently updated the same day, is no longer enrolling patients. Nevertheless, there are 1,032 other studies currently looking for volunteers to join in their medical investigation."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

COVID-19 Bivalent Booster Megastudy

2022. "COVID-19 Bivalent Booster Megastudy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05607082.